Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

被引：0
|
作者：
T. Shiroiwa
T. Fukuda
K. Shimozuma
M. Mouri
Y. Hagiwara
H. Doihara
H. Akabane
M. Kashiwaba
T. Watanabe
Y. Ohashi
H. Mukai
机构：
[1] National Institute of Public Health,Department of Health and Welfare Services
[2] Ritsumeikan University,Department of Biomedical Sciences, College of Life Sciences
[3] Kanagawa Academy of Science and Technology (KAST),Department of Biostatistics, School of Public Health
[4] The University of Tokyo,Breast and Endocrine Surgery Department
[5] Okayama University Hospital,Department of Surgery
[6] Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital,Department of Surgery
[7] Iwate Medical University,Department of Breast Surgery
[8] Sendai Medical Center,Department of Integrated Science and Engineering
[9] Chuo University,Division of Breast and Medical Oncology
[10] National Cancer Center Hospital East,undefined
来源：
Quality of Life Research | 2017年 / 26卷
关键词：
Breast cancer; EQ-5D; Health-related quality of life; Randomized controlled trial; S-1; Taxane;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：445 / 453
页数：8
相关论文
共 47 条
  • [41] NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)
    Winther, S. B.
    Skuladottir, H.
    Hofsli, E.
    Shah, C-H.
    Yilmaz, M. K.
    Osterlund, P. J.
    Berglund, A.
    Glimelius, B.
    Qvortrup, C.
    Sorbye, H.
    Pfeiffer, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
    Cremolini, C.
    Loupakis, F.
    Antoniotti, C.
    Lonardi, S.
    Masi, G.
    Salvatore, L.
    Cortesi, E.
    Tomasello, G.
    Spadi, R.
    Zaniboni, A.
    Tonini, G.
    Barone, C.
    Vitello, S.
    Longarini, R.
    Bonetti, A.
    D'Amico, M.
    Di Donato, S.
    Granetto, C.
    Boni, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1188 - 1194
  • [43] BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC)
    Hurvitz, Sara A.
    Andre, Fabrice
    Burris, Howard A.
    Toi, Masakazu
    Buyse, Marc E.
    Sahmoud, Tarek
    Mukhopadhyay, Pabak
    Massacesi, Cristian
    Taran, Tanya
    Ko, Jennifer
    Rupin, Matthieu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial
    Denda, Tadamichi
    Takashima, Atsuo
    Gamoh, Makio
    Iwanaga, Ichiro
    Komatsu, Yoshito
    Takahashi, Masanobu
    Nakamura, Masato
    Ohori, Hisatsugu
    Sakashita, Akiko
    Tsuda, Masahiro
    Kobayashi, Yoshimitsu
    Baba, Hideo
    Kotake, Masanori
    Ishioka, Chikashi
    Yamada, Yasuhide
    Sato, Atsushi
    Yuki, Satoshi
    Morita, Satoshi
    Takahashi, Shin
    Yamaguchi, Tatsuro
    Shimada, Ken
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 296 - 306
  • [45] Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) plus /- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)
    Rugo, Hope S.
    Barry, William T.
    Moreno-Aspitia, Alvaro
    Lyss, Alan
    Huebner, Luke
    Mayer, Erica L.
    Naughton, Michael
    Layman, Rachel M.
    Carey, Lisa A.
    Somer, Robert A.
    Toppmeyer, Debra
    Velasco, Mario
    Perez, Edith A.
    Hudis, Cliff A.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
  • [46] Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55 Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed
    Eriksson, Pontus
    Sjodahl, Gottfrid
    Liedberg, Fredrik
    EUROPEAN UROLOGY, 2017, 72 (05) : E135 - E136
  • [47] Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?
    Powles, Thomas
    de Liano, Alfonso Gomez
    Ackerman, Charlotte
    EUROPEAN UROLOGY, 2017, 72 (05) : E137 - E138
12345